Effects of intravenous autologous bone marrow derived mesenchymal stem cells in patients with chronic heart failure

Effects of intravenous autologous bone marrow derived mesenchymal stem cells in patients with chronic heart failure - Intravenous bone marrow derived mesenchymal stem cells for chronic heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025233

Enrollment

Registered

2017-01-01

Start date

2017-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

Culture of autologous bone marrow derived mesenchymal stem cells and intravenous injection of cultured cells

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. NYHA II or III, LVEF less than 45% 2. BNP more than 50 pg/ml 3. Receiving medical therapy including ACE inhibitor and be-ta blocker for more than 12 months

Exclusion criteria

Exclusion criteria: 1. Unstable heart failure 2. Patients with unstable angina 3. Current cardiac surgery and device therapy 4. Life expectancy less than 6 months 5. Severe liver and kidney failure

Design outcomes

Primary

Measure	Time frame
Improvement of left ventricular ejection fraction on echocardiography	—

Secondary

Measure	Time frame
change of BNP and high sensitive troponin	—

Countries

Japan

Contacts

Public ContactYukihito Sato

Hyogo Prefectural Amagasaki General Medical Center Cardiology

cardioys@kuhp.kyoto-u.ac.jp06-6480-7000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026